SGS Adds GMP DNA Sequencing Capabilities at Glasgow Facility

Dec 12, 2017
By Pharmaceutical Technology Editors
Volume 13, Issue 1

SGS, a provider of bio/pharmaceutical, analytical, and bioanalytical solutions, has introduced a Sanger sequencing service at its Glasgow, United Kingdom, laboratory to support genetic stability testing and perform identity testing on cell banks, plasmids, and viral seeds/vectors. The service is now available under good manufacturing practice (GMP) conditions to clients from December 2017.

Sanger sequencing is a method of DNA sequencing based on the selective incorporation of chain-terminating deoxynucleotides by DNA polymerase during in-vitro DNA replication. Applications include cell bank characterization, virus seed and plasmid identity testing, and genetic stability testing of cell banks. The new service is supported by an investment in ABI Life Technologies’ validated 3500xl DNA sequencing technology and will complement existing services for this testing, to provide comprehensive analysis and characterization solutions for clients involved in the production and manufacturing of biopharmaceutical products.

The Glasgow facility became part of SGS in 2012 following the acquisition of biopharmaceutical contract testing organization Vitrology Limited, which specializes in biosafety testing. An expansion of the facility in 2014 added an additional 500 m² of laboratory space.

SGS has 20 laboratories offering contract analytical and bioanalytical services across in North America, Europe, and Asia. The company delivers harmonized solutions to large pharmaceutical and biotechnology firms. In addition to testing services for the bio/pharmaceutical market, SGS also provides Phase I­–IV clinical trial management, and services encompassing data management and statistics, pharmacokinetic/pharmacodynamic modeling and simulation, pharmacovigilance, and regulatory consultancy.

Source: SGS

native1_300x100
lorem ipsum